Riassunto: Incyte annuncia dati a lungo termine relativi allo studio di fase 3 TRuE-AD4l di 24 settimana sulla crema Opzelura® (ruxolitinib) in soggetti adulti affetti da dermatite atopica moderata

Key Takeaway: Incyte has announced long-term data from the Phase 3 TRuE-AD4 study, which evaluated the efficacy of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis over a 24-week period. The results are expected to provide insights into the treatment's effectiveness and safety profile. Further details on the findings are anticipated.